Purpose: To explore patterns of time to failure in men receiving high doses of permanent seed brachytherapy with or without external beam radiation therapy as a function of risk status.
Purpose
There is emerging evidence that time to biochemical failure is a robust prognostic factor for prostate cancer mortality and overall mortality in men receiving definitive radiotherapy [13] . Interval to biochemical failure is also highly prognostic for prostate cancer mortality in men un dergoing prostatectomy [4] . One cause of early biochemi cal failure is occult micrometastatic disease present at time of treatment. Regardless of efficacy of local treatment, individuals with occult metastases often have early recur rence with relatively poor prognosis, due to unappreciated stage IV disease at presentation. Early biochemical failure can also occur in men with strictly localized disease, if local therapy is inadequate to provide even short term local con trol. This can be due to radioresistant local disease, inade quate radiation dose delivered, inadequate surgical margin or deficient radiation targeting.
As with early failures, late failures can be caused either by more gradual progression of slow growing occult meta static disease or gradual recurrence of partially treated local disease. In modern radiation therapy literature, there contin ues to be a relatively large number of late failures (> 4 years), even with dose escalation to 78 Gy or over 80 Gy [5, 6] . The purpose of this paper is to explore whether further dose es calation would lead to a decrease in late failures. If so, partic ularly for high risk patients, this might suggest that the pre ponderance of late failures in recent studies may represent incomplete ability to eradicate local disease rather than high incidence of slow growing occult metastases at presentation.
In this paper, we examine a cohort of men who received high local radiation doses for clinically localized prostate cancer. Consistently, high implant D 90 s with sizeable mar gins were utilized for all patients, and the majority of in termediate risk and almost all high risk patients received supplemental external beam radiation. Our goal was to explore patterns in time to failure in men receiving high local radiation doses to better understand the role of im proved local control and the implications for long term prostate cancer outcomes. We also hope to provide some insight into the question of what portion of patients (par ticularly high risk patients) are potentially curable, in ef fect, without viable metastatic disease at presentation.
Material and methods
From March 1995 till July 2010, 2234 consecutive pa tients underwent definitive permanent interstitial brachythera py by a single brachytherapist (GSM). All pa tients were treated more than three years prior to analysis. All biopsy samples were reviewed by a single pathologist (EA) to minimize inconsistencies in pathologic grading. Preplanning technique, intraoperative approach and dosim etric evaluation have been described in detail [7, 8] 4 Gy covering prostate, seminal vesicles, and at-risk pelvic nodes. ADT, when utilized, was initiated 3 months prior to implantation, and consisted of a lutein izing hormone-releasing hormone (LHRH) agonist and an anti-androgen. The range of ADT duration was 3-36 months. Indications for ADT were prostate cytoreduction prior to implant and for men with higher risk disease.
For prostate implants, the target volume (PTV) was the prostate plus a periprostatic margin of 45 mm, except posteriorly to limit rectal dose. Median prostate volume was 32.0 cm³, while the median planning volume was 60.6 cm³. Also included in the brachytherapy PTV was the proximal 1.0 cm of seminal vesicles.
The primary radionuclide utilized was 103 Pd (Theragenics model 200), while the other radionuclide 125 I (Amersham model 6711 and its stranded form) was not implanted after 2003. Dosimetry was based on day zero computerized tomography (CT) studies. The overall pop ulation mean D 90 (minimum dose received by 90% of the PTV) was 119.1% of prescription dose. The mean V 100 for the study population was 96.6% of the PTV. These rela tively large D 90 and V 100 values have been associated with improved treatment outcomes [9, 10] .
Biologically effective dose (BED) was calculated using the algorithm recommended by American Association of Physicist in Medicine (AAPM) Task Group 137 to provide consistency in radiobiological comparisons between in stitutions [11] . This consensus group recommends a uni form set of algorithms and radiobiological indices to fa cilitate consistency in routine outcome reporting. The Task Group values used in this work were: α = 0.15 Gy -1 , β = 0.05 Gy -2 , α/β = 3.0 Gy, T pot = 42 days, and repair half-life = 16 min.
The brachytherapy BED was based on the day 0 D 90, and the total BED added any contribution from external beam radiation.
Patient demographics and treatment details are pro vided in Table 1 , which is stratified by National Compre hensive Cancer Network (NCCN) risk groups. Patients were monitored by physical examination including dig ital rectal examination, and serum PSA determination at 3 and 6 months intervals. Patient survival was confirmed for all patients not only by PSA reports, but also by fre quent quality of life surveys (QoL) (by telephone or occa sionally mail) at least 25 times during the first five years following brachytherapy, and never less than twice per year thereafter. The primary outcome measures were time to biochemical failure, time to distant metastases, and time to prostate cancer death. We also assessed percent of men with biochemical failure who ultimately progressed to metastases or prostate cancer death, and the time from biochemical failure to those outcomes. Biochemical failure was defined as PSA > 0.40 ng/mL after nadir [12] . This definition has been shown to be particularly sensitive in detecting treatment failure [12] . Cause of death was deter mined for each deceased patient. Patients with metastatic prostate cancer or castrate resistant disease without obvi ous metastases who died of any cause were classified as dead of prostate cancer. All other deaths were attributed to the immediate cause of death. In our population, 40% of deaths were attributable to cardiovascular disease, 33% to nonprostate cancer deaths, 8% to respiratory disease, 4% to prostate cancer, and 15% to other causes.
Continuous clinical and treatment variables were com pared across groups, using oneway analysis of variance (ANOVA). Categorical variables were compared using a chisquare analysis. Biochemical survival, metastases free survival, cause specific mortality, and all cause mortality were determined using cumulative incidence and cumula tive survival curves. With the population stratified by low, intermediate, and high risk disease, biochemical failure rates were determined by competing risk analysis where non-prostate cancer death was the competitor. Significant predictors for prostate specific, biochemical progression free, and overall survival were first determined by univar iate regression analysis, and those variables with p < 0.010 were included in multivariate analysis. Competing risk regression was employed for prostate specific and pro gression free survival analyses. All statistical analyses used Stata version 13.0 software (StataCorp, College Station, TX, USA), and statistical significance was defined a p < 0.05.
Results
For the population, 10 year overall mortality and com peting risk adjusted biochemical failure, and causespe cific mortality were 22.5%, 4.4%, and 1.3%, respectively (Fig. 1) . No metastases developed after 5 years, and the cumulative incidence of distant metastases at 5 years and beyond was 1.4%. The cumulative ten year competing risk adjusted biochemical failure rate for men with low, intermediate, and high risk disease was 1.3%, 4.8%, and 10.0%, respectively (Fig. 2) . The median time to failure (TTF) was 2.8 years. Because completeness of follow up influences the va lidity of survival curves, Table 2 lists mean days since last contact of living patients for mortality and days since last PSA for biochemical failure. The mean elapsed days since last patient contact (64 ± 117 days), and last PSA (123 ± 164 days) were considerably greater than the medians (50 days and 99 days, respectively) because of a few out liers. For survival status, only 11 of 1713 living patients had not been contacted in the year preceding database closure. Nine of the eleven had either advanced dementia or were dying from a disease other than prostate cancer, and the patient or caregiver felt that further follow up and PSA testing were pointless. For biochemical survival fol low up, PSA testing was more than one year delinquent in 57 of 1664 living, nonfailed men. The most common reason for noncompliance was the inconvenience and expense of testing, followed by perceived futility among those dying from nonprostate causes.
There was no biochemical failure in any of the 745 pa tients followed for more than 9.2 years, out to the maxi mum PSA follow up of 18.2 years. The median TTF among the biochemical failures was 2.6 years, and there was no significant difference between risk groups (p = 0.077) where the mean TTF for low, intermediate, and high risk (Fig. 3) , 79.3% of biochemical failures occurred within the first four years, compared to 88.2% of failures in men with high risk disease (Fig. 4) .
In men who died from prostate cancer, the median time from treatment failure to death was 4.2 years. Me dian time from treatment to development of metastases was 2.3 years. Overall, 96.7% of metastases occurred within the first 4 years. Table 3 consists of univariate and multivariate analyses of cause-specific, biochemical progression free, and over all survival. Of the eight variables identified as significant predictors of biochemical progression free survival, six of them -PSA, Gleason score, clinical stage, percent positive biopsies, and ADT duration are strongly correlated with NCCN risk grouping. For overall survival, only two of the 15 variables included in the multivariate analysis were significant predictors: age at implant and tobacco use.
Discussion
Early failure after definitive prostate cancer treatment was significantly more common in the 1990s when low er radiation doses were employed. As an example, in the D'Amico et al. landmark 1998 paper comparing bio chemical outcomes between prostatectomy, surgery and brachytherapy [13] , the authors report on high risk men treated with 66 Gy of radiotherapy without ADT. Over 50% of men had failed therapy before 3 years. Likewise, Kestin et al. [14] reported in 1999 on William Beaumont pa tients, primarily Gleason ≤ 7, treated to a median dose of 66.6 Gy. They found a median time to failure of less than two years, with a failure rate approximating 50% at three years and relatively few failures after that time. These high rates of early local failure were likely due to both the more advanced disease common during that era, and to the in adequacy of 66 Gy to reliably eradicate local disease.
The increase in radiotherapy dose to 70 Gy with and without the addition of androgen deprivation, led to a de crease in early failures. In the milestone EORTC trial pub lished by Bolla et al. [15] , which demonstrated the survival advantage of androgen deprivation combined with 70 Gy radiotherapy, biochemical failures were relatively uncom mon in either arm in the first three years. However, ulti mate biochemical failure rates were high, with the signif icant majority of treatment failures occurring in the fourth year and later. At 3 years, biochemical failure was approx imately 15-20% in both arms. However, by year 8, failure rates were approximately 50% in the ADT arm and 80% in the radiotherapy only arm.
As radiation doses have been increased, the overall rate of treatment failure has decreased, though the proportion of late treatment failures remains high. The M.D. Anderson dose escalation trial reported by Kuban et al. [5] , compared men receiving 70 Gy to those receiving 78 Gy. With dose es calation, early treatment failures were uncommon; the over all number of treatment failures decreased; and the number of late failures decreased. However, the significant majority of treatment failures continued to occur after four years. The PROG dose escalation study [16] has shown similar re sults, with the significant majority of low and intermediate risk failures occurring in the fourth year or later in the high dose arm. Recently, Zelefsky et al. [6] reported on their pro spective dose escalation, comparing men treated to < 81 Gy, with those treated up to 86.4 Gy. They found a modest de crease in treatment failures within the first four years, with a more prominent decrease in later failures. Nonetheless, even at doses > 81 Gy, the vast majority of failures occurred after four years, whether or not androgen deprivation was used. And overall treatment failure at ten years remained high at approximately 25% for intermediate risk patients and 45% for high risk patients. In high risk patients, the combination of moderate dose external beam radiation ther apy, a brachytherapy boost and ADT decreases biochemical failure and prostate cancer deaths, when compared to pa tients treated with external beam and ADT [17] .
These findings demonstrate that some early failures and many late failures can be eliminated with dose esca lation to approximately 80 Gy, presumably because many of the failures at lower doses were related to inadequate Years to biochemical failure Years to biochemical failure local disease control. However, the preponderance of late failures even at dose levels of 7886 Gy, leaves open the question as to whether men in those studies had occult metastases at presentation or were potentially curable with even further dose escalation. With mean and median brachytherapy day 0 implant D 90 s of 119%, generous margins with the prostate volume expanded by a factor of 1.9 to the planning volume, and ex tensive use of supplemental external beam radiotherapy, the patients in our implant population received relatively high dose escalation. Using the AAPM radiobiological formalism [11] , 86.4 Gy of prostate external beam radiation has a BED of 131 Gy, while the mean total BED for our population ranged from 133 Gy for low risk men to 157 Gy, and 164 Gy in inter mediate and high risk men, respectively (Table 1) .
In patients with positive biopsies at the prostate base treated with brachytherapy monotherapy at M.D. Ander son, the 10year biochemical progression free survival as 93.5%, and all failures occurred prior to 6 years [18] . A much larger population in a recent report by Morris et al. [19] on brachytherapy monotherapy in low and interme diate risk patients with median and maximum follow up of 7.5 years, and 13 years had 16% of failures occurring at < 3 years and 10% > 8 years. Using only 125 I seeds, their mean D 90 was 151 Gy which translates to an AAPM BED of 116 Gy. In our low to intermediate risk cohort, 58.6% (34/58) of failures were within 3 years, while only 2 pa tients failed after 8 years.
Our rate of early treatment failures is roughly similar to the rates in the more recent external beam dose escala tion studies. However, the rate of late treatment failures is much lower in our series than in those studies. The recent dose escalated external beam series have a high propor tion of treatment failures five or more years after treat ment; whereas 91% (84/92) of treatment failures in our series occurred within the first 5 years. This supports the hypothesis that in modern cohorts, even among men with high risk disease, the number of men who experience early failures and are "incurable" due to presence of occult me tastases prior to treatment is quite small. As well, it would appear that most late treatment failures in current dose es calated external beam series are not the result of untreated [20] in 1991, who found that even in men undergoing retropu bic brachytherapy implants, durable local control led to a substantial reduction in development of metastases.
Limitations
The strengths of this work are that low, intermediate and high risk patients were treated with a consistent im plant philosophy and pattern of dose escalation, that the dose escalation parameters were well documented, and that no patients were lost to follow up. In general, lower risk patients received high quality brachytherapyalone with day 0 D 90 s of approximately 120%. Higher risk pa tients received supplemental external beam radiotherapy, followed by equally high quality implants with day 0 D 90 s of approximately 120%. One limitation is that this study was not a randomized trial comparing TTF between dose escalated brachytherapy with and without external beam radiotherapy versus dose escalated external beam radio therapy alone. In addition, although the premise that early biochemical failures are due to subclinical distant metastases at diagnosis, this remains unproven due to the inability of current radiographic technologies to identify such early metastatic disease. Nevertheless, based on the results above, we feel comfortable with the conclusion that there is a low burden of micrometastatic disease at presentation in modern day patient cohorts similar to ours; and that effective dose escalation with brachythera py can lead to very successful treatment outcomes.
Conclusions
Aggressive radiation dose escalation provided by brachytherapy for men with low, intermediate, and high risk disease leads to low levels of late treatment failures. This supports the hypothesis that the great majority of prostate cancer patients, even those with high risk disease are with out micrometastatic disease on presentation, and therefore are potentially curable with adequate dose escalation.
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